<DOC>
	<DOCNO>NCT01033981</DOCNO>
	<brief_summary>Primary Hypothesis : The therapy Sunitinib represent good cost-effectiveness IFN-α first-line treatment metastatic Renal Cell Carcinoma ( mRCC ) Central America Caribbean country</brief_summary>
	<brief_title>Cost Effectiveness Of Sunitinib In Central America And Caribbean</brief_title>
	<detailed_description>This study terminate 03Feb2011 due fact anticipated number patient expect reach . The date cessation drug January 27 , 2011 . There intervention treatment administration drug ; study observe treatment collect data . As study dependent arrival new patient metastatic renal cancer , low incidence , study terminate . Efficacy , adverse event safety issue factor terminate study . Lack patient reason .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Evidence personally sign ( legally acceptable representative ) date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Adult ( 18 year old old ) men woman confirm diagnosis mRCC treat Sutent , IFNα Bevacizumab + IFN ; select institution . Adult men woman RCCm treat medication Sutent , IFNα Bevacizumab + IFN . Adult men woman mRCC palliative care . Adult men woman RCC without metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>cost effectiveness</keyword>
	<keyword>Sunitinib Central America Caribbean Metastatic Renal Cell Carcinoma</keyword>
</DOC>